These findings were corroborated in a separate study, where treatment of gefitinib- and erolotinib-resistant NSCLC with the STAT3 inhibitor W2014-S sensitized these cells to therapy in vitro and enhanced the anti-tumor efficacy of gefitinib in tyrosine kinase resistant lung cancer xenografts in vivo [238]. Here, STAT3 is linked to non-small cell lung carcinoma.